2017;76:196\202. repeated clinical α-Terpineol use of MSCs should be limited to autologous or cross\matched allogeneic MSCs. When nonCcross\matched allogeneic MSCs are used in single MSC dose applications, presensitization α-Terpineol against donor MHC should be assessed. Keywords: allogeneic, alloimmunization, antibody, autologous, cross\match, humoral, innate, intra\articular, major histocompatibility complex (MHC), MSC Autologous and matched mesenchymal stromal cell (MSC) intra\articular transplantation resulted in increased stromal derived factor\1 and endogenous progenitors, whereas mismatched MSCs resulted in local inflammation, not different to lipopolysaccharide (LPS) injection, and antibody dependent cytotoxicity of MSCs. Significance statement The mesenchymal stromal cell (MSC) regenerative medicine dogma has been one of absolute immune privilege. This notion, taken together with the commercial advantages of allogeneic cell lines, has led to a majority of preclinical and clinical studies utilizing nonCcross\matched MSCs despite lack of scientific evidence for allogeneic superiority. This study provides strong evidence that use of nonCcross\matched allogeneic MSCs may be the Achilles’ heel for reliable and predictable MSC efficacy. This article will accelerate a paradigm shift away from nonCcross\matched allogeneic MSC clinical trials and pave the way to regulatory approval for disorders that currently do not have adequate medical therapies. 1.?INTRODUCTION Mesenchymal stromal cell (MSC) therapy is one of the most heavily studied therapeutic modalities for which there are no market authorizations in the United States. The reason for the lack of regulatory approval could be that despite decades of MSC research and repeated preclinical success, late phase clinical trials and post approval monitoring have failed to demonstrate α-Terpineol consistent therapeutic effects. 1 , 2 , 3 Lack of efficacy has been proposed to be due to nonuniformity of MSC preparation and application techniques. 3 , 4 , 5 Certainly, the immune\privileged status of α-Terpineol MSCs has been questioned and the possible negative effect of immunological incompatibility on primary efficacy endpoints of MSC therapy has been considered. 1 , 6 Clinical investigations into the effect of major histocompatibility complex (MHC) mismatched allogeneic MSCs suggest that mismatch does not alter efficacy, but reports have been limited and immunological monitoring has not been stringent. 7 , 8 Although donor\specific antibody production against allogeneic MSCs has been confirmed in people, 9 , 10 , 11 , 12 , 13 , 14 , 15 nonhuman primates, 16 , 17 and horses, 18 , 19 the effects of mismatched allogeneic MSCs on MSC persistence remains unknown. 1 Certainly, reduced persistence with concomitant loss of function of allogeneic MSC\gene therapy constructs compared with autologous or syngeneic MSCs has been confirmed in laboratory animals. 17 , 20 , 21 , 22 , 23 , 24 Still, the survival time of allogeneic MSCs is usually significantly longer than allogeneic fibroblasts, likely due to MSC immune\evasiveness. 21 This immune evasion may explain why there is clinical safety with allogeneic MSC injection, and acute rejection responses do not occur, even if there is allorecognition with resultant cytotoxicity. Despite the value of Rabbit Polyclonal to CNGB1 laboratory animal models in science, preclinical success often fails to result in clinical application. 25 Poor α-Terpineol translation of preclinical findings is in part due to the use of inbred laboratory animals that lack the diversity of man. 3 , 25 Specific to the study of MSC immune\compatibility, results from syngeneic or inbred animals are not translatable to human patients because of the lack of MHC diversity. 3 , 6 Conversely, the horse has wide genetic diversity with frequent MHC recombination events and is an ideal model to study immune compatibility of allogeneic cell therapy. 26 , 27 , 28 Additionally, the horse is well\recognized for its value as a preclinical model for joint injury as the equine articular joint closely mimics that of man in the cartilage thickness and collagen distribution as well as the architecture of subchondral bone. 29 , 30 Given that nearly 20% of clinical trials for MSC therapy in man are for bone and cartilage disease, the equine articular model is ideal for preclinical study of allogeneic MSC therapy. 31 We compare repeated intra\articular injection of clinically prepared MHC matched,.